Literature DB >> 29729004

Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies.

F Pacini1, F Basolo2, R Bellantone3, G Boni4, M A Cannizzaro5, M De Palma6, C Durante7, R Elisei8, G Fadda9, A Frasoldati10, L Fugazzola11,12, R Guglielmi13, C P Lombardi3, P Miccoli2, E Papini13, G Pellegriti14, L Pezzullo15, A Pontecorvi16, M Salvatori17, E Seregni18, P Vitti8.   

Abstract

BACKGROUND: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent.
METHODS: Six scientific Italian societies entitled to cure thyroid cancer patients (the Italian Thyroid Association, the Medical Endocrinology Association, the Italian Society of Endocrinology, the Italian Association of Nuclear Medicine and Molecular Imaging, the Italian Society of Unified Endocrine Surgery and the Italian Society of Anatomic Pathology and Diagnostic Cytology) felt the need to develop a consensus report based on significant scientific advances occurred in the field.
OBJECTIVE: The document includes recommendations regarding initial evaluation of thyroid nodules, clinical and ultrasound criteria for fine-needle aspiration biopsy, initial management of thyroid cancer including staging and risk assessment, surgical management, radioiodine remnant ablation, and levothyroxine therapy, short-term and long-term follow-up strategies, and management of recurrent and metastatic disease. The objective of this consensus is to inform clinicians, patients, researchers, and health policy makers about the best strategies (and their limitations) relating to the diagnosis and treatment of differentiated thyroid cancer.

Entities:  

Keywords:  Radioiodine; Thyroid cancer; Thyroid nodules; Thyroid surgery

Mesh:

Year:  2018        PMID: 29729004     DOI: 10.1007/s40618-018-0884-2

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  72 in total

Review 1.  Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients.

Authors:  M G Castagna; S Cantara; F Pacini
Journal:  J Endocrinol Invest       Date:  2016-06-27       Impact factor: 4.256

2.  Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.

Authors:  Ewa Ruel; Samantha Thomas; Michaela Dinan; Jennifer M Perkins; Sanziana A Roman; Julie Ann Sosa
Journal:  J Clin Endocrinol Metab       Date:  2015-02-02       Impact factor: 5.958

3.  Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer.

Authors:  Désirée Deandreis; Carole Rubino; Hernan Tala; Sophie Leboulleux; Marie Terroir; Eric Baudin; Steve Larson; James A Fagin; Martin Schlumberger; R Michael Tuttle
Journal:  J Nucl Med       Date:  2016-10-13       Impact factor: 10.057

4.  Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.

Authors:  Eleonora Molinaro; Carlotta Giani; Laura Agate; Agnese Biagini; Letizia Pieruzzi; Francesca Bianchi; Federica Brozzi; Claudia Ceccarelli; David Viola; Paolo Piaggi; Paolo Vitti; Furio Pacini; Rossella Elisei
Journal:  J Clin Endocrinol Metab       Date:  2013-04-26       Impact factor: 5.958

5.  Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.

Authors:  Christian Pötzi; Abbas Moameni; Georgios Karanikas; Josef Preitfellner; Alexander Becherer; Christian Pirich; Robert Dudczak
Journal:  Clin Endocrinol (Oxf)       Date:  2006-10       Impact factor: 3.478

6.  Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer.

Authors:  Rosália P Padovani; Eyal Robenshtok; Matvey Brokhin; R Michael Tuttle
Journal:  Thyroid       Date:  2012-07-10       Impact factor: 6.568

7.  A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases.

Authors:  Concetto Regalbuto; Pasqualino Malandrino; Andrea Tumminia; Rosario Le Moli; Riccardo Vigneri; Vincenzo Pezzino
Journal:  Thyroid       Date:  2011-04       Impact factor: 6.568

8.  Ipsilateral Central Neck Dissection Plus Frozen Section Examination Versus Prophylactic Bilateral Central Neck Dissection in cN0 Papillary Thyroid Carcinoma.

Authors:  Marco Raffaelli; Carmela De Crea; Luca Sessa; Guido Fadda; Chiara Bellantone; Celestino P Lombardi
Journal:  Ann Surg Oncol       Date:  2015-02-05       Impact factor: 5.344

9.  Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis.

Authors:  Sophie Leboulleux; Carole Rubino; Eric Baudin; Bernard Caillou; Dana M Hartl; Jean-Michel Bidart; Jean-Paul Travagli; Martin Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2005-07-19       Impact factor: 5.958

10.  Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH.

Authors:  H Tala; R Robbins; J A Fagin; S M Larson; R M Tuttle
Journal:  J Clin Endocrinol Metab       Date:  2011-05-11       Impact factor: 5.958

View more
  45 in total

1.  Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study.

Authors:  P Premoli; M L Tanda; E Piantanida; G Veronesi; D Gallo; E Masiello; S Rosetti; C Cusini; F Boi; J Bulla; R Rodia; S Mariotti; V Capelli; M Rotondi; F Magri; L Chiovato; R Rocchi; M C Campopiano; R Elisei; P Vitti; F Barbato; T Pilli; M G Castagna; F Pacini; L Bartalena
Journal:  J Endocrinol Invest       Date:  2019-07-20       Impact factor: 4.256

2.  Indication for radioiodine remnant ablation in differentiated thyroid cancer patients: does 2018 Italian consensus change anything?

Authors:  R Forleo; N Fralassi; F Maino; M Capezzone; L Brilli; T Pilli; S Cantara; M G Castagna
Journal:  J Endocrinol Invest       Date:  2020-05-09       Impact factor: 4.256

Review 3.  Total thyroidectomy versus thyroid lobectomy in the treatment of papillary carcinoma.

Authors:  Marco Raffaelli; Serena Elisa Tempera; Luca Sessa; Celestino Pio Lombardi; Carmela De Crea; Rocco Bellantone
Journal:  Gland Surg       Date:  2020-01

4.  Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.

Authors:  Alfredo Campennì; Ernesto Amato; Riccardo Laudicella; Angela Alibrandi; Davide Cardile; Salvatore Antonio Pignata; Francesco Trimarchi; Rosaria Maddalena Ruggeri; Lucrezia Auditore; Sergio Baldari
Journal:  Endocrine       Date:  2019-03-14       Impact factor: 3.633

Review 5.  Total thyroidectomy vs. lobectomy in differentiated thyroid cancer: is there a reasonable size cut-off for decision? A narrative review.

Authors:  Daniele Barbaro; Giancarlo Basili; Gabriele Materazzi
Journal:  Gland Surg       Date:  2021-07

6.  Risk of recurrence in patients with papillary thyroid carcinoma and minimal extrathyroidal extension not treated with radioiodine.

Authors:  P W Rosario; G Mourão; M R Calsolari
Journal:  J Endocrinol Invest       Date:  2018-10-23       Impact factor: 4.256

Review 7.  Skeletal health in patients with differentiated thyroid carcinoma.

Authors:  M Cellini; M Rotondi; M L Tanda; E Piantanida; L Chiovato; P Beck-Peccoz; Andrea Lania; G Mazziotti
Journal:  J Endocrinol Invest       Date:  2020-07-21       Impact factor: 4.256

8.  Modulating the extension of thyroidectomy in patients with papillary thyroid carcinoma pre-operatively eligible for lobectomy: reliability of ipsilateral central neck dissection.

Authors:  M Raffaelli; C De Crea; L Sessa; S E Tempera; G Fadda; A Pontecorvi; R Bellantone
Journal:  Endocrine       Date:  2020-08-20       Impact factor: 3.633

9.  Total Thyroidectomy Versus Lobectomy for Thyroid Cancer: Single-Center Data and Literature Review.

Authors:  Carla Colombo; Simone De Leo; Marta Di Stefano; Matteo Trevisan; Claudia Moneta; Leonardo Vicentini; Laura Fugazzola
Journal:  Ann Surg Oncol       Date:  2021-02-10       Impact factor: 5.344

10.  Repeat Ultrasonography in the First Years after Therapy with Radioiodine Is Not Necessary in Most Patients with Papillary Thyroid Carcinoma when Postoperative Ultrasonography Is Negative: A Reduction of Costs and False-Positives.

Authors:  Pedro Weslley Rosario; Gabriela Franco Mourão; Maria Regina Calsolari
Journal:  Eur Thyroid J       Date:  2018-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.